Development of a Cell-Based Enzyme-Linked Immunosorbent Assay for High-Throughput Screening of HIV Type 1 Entry Inhibitors Targeting the Coreceptor CXCR4

AIDS Research and Human Retroviruses

Volumn 19, Issue 11, 2003, Pages 947-955

  Zhao, Qian ^a   Lu, Hong ^a   Schols, Dominique ^b   De Clercq, Erik ^b   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 12G5; PROTEINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 14012; T 22; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ROBOTICS; TEMPERATURE;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL FUSION; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SENSITIVITY AND SPECIFICITY;

EID: 0344825899     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322588297     Document Type: Article

References (67)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-767.
2. Lifson JD, Reyes GR, McGrath MS, Stein BS, and Engleman EG: AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986;232:1123-1127.
3. Sattentau QJ and Weiss RA: The CD4 antigen: Physiological ligand and HIV receptor. Cell 1988;52:631-633.
4. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381: 661-666.
6. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, and Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996;384:184-187.
7. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
8. Moore JP, Jameson BA, Weiss RA, and Sattentau QJ: The HIV-cell fusion reaction. In: Viral Fusion Mechanisms. (Bentz J. ed.) CRC Press, Boca Raton, FL, 1993, pp. 233-289.
9. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
10. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-428.
11. Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, and Weiss RA: A new classification for HIV-1 [letter]. Nature 1998;391:240.
12. Baba M, Miyake H, Okamoto M, Iizawa Y, and Okonogi K: Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res Hum Retroviruses 2000;16:935-941.
13. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, and Clapham PR: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-8360.
14. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
15. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, and Schuitemaker H: Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999;179:254-258.
16. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, and Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
17. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, and Sodroski JG: The antigenic structure of the HIV gp120 evelope glycoprotein. Nature 1998;393:705-711.
18. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
19. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, and Sodroski J: A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-1953.
20. Jiang S: HIV-1 - co-receptor binding. Nature Med 1997;3:367-368.
21. Labrosse B, Treboute C, Brelot A, and Alizon M: Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol 2001;75:5457-5464.
22. Brelot A, Heveker N, Pleskoff O, Sol N, and Alizon M: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 1997;71:4744-4751.
23. Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, Hoxie JA, Peiper SC, and Doms RW: Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 1997;94:6426-6431.
24. Brelot A, Heveker N, Montes M, and Alizon M: Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 2000;275:23736-23744.
25. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA, and Clapham PR: Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71:1692-1696.
26. Strizki JM, Turner JD, Collman RG, Hoxie J, and Gonzalez-Scarano F: A monoclonal antibody (12G5) directed against CXCR4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB). J Virol 1997;71:5678-5683.
27. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-835.
28. Schols D, Struyf S, Van Damme J, Este JA, Henson G, and De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
29. Donzella GA, Schols D, Lin SW, Este J A, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, and Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998;4:72-77.
30. Hatse S, Princen K, Bridger G, De Clercq E, and Schols D: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002;527:255-262.
31. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, and Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
32. Tamamura H, Otaka A, Murakami T, Ishihara T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, and Fujii N: Interaction of an anti-HIV peptide, T22, with gp120 and CD4. Biochem Biophys Res Commun 1996;219:555-559.
33. Neurath AR, Jiang S, Strick N, Lin K, Li Y-Y, and Debnath AK: Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nature Med 1996;2:230-234.
34. Fujii N, Nakashima H, and Tamamura H: The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 2003;12:185-195.
35. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
36. Jiang S, Lin K, Strick N, and Neurath AR: HIV-1 inhibition by a peptide. Nature 1993;365:113.
37. Lu H, Zhao Q, Xu Z, and Jiang S: Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): Application for rapid screening of HIV-1 fusion inhibitors. J Virol Methods 2003;107:155-161.
38. Jiang S, Radigan L, and Zhang L: A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc SPIE 2000;3926:212-219.
39. Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, Schweickart VL, Raport CJ, and Emerman M: Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997;233:193-198.
40. Nakashima H, Masuda M, Murakami T, Koyanagi Y, Matsumoto A, Fujii N, and Yamamoto N: Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): A possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992;36:1249-1255.
41. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, and Nakashima H: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-1723.
42. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA, and Clapham PR: Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71:1692-1696.
43. Huerta L, Lamoyi E, Baez-Saldana A, and Larralde C: Human immunodeficiency virus envelope-dependent cell-cell fusion: A quantitative fluorescence cytometric assay. Cytometry 2002;47:100-106.
44. Forster R, Emrich T, Voss C, and Lipp M: A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA. Biochem Biophys Res Commun 1993;196:1496-1503.
45. Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, Terakawa Y, Tamamura H, Ibuka T, Murakami T, et al.: A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem Biophys Res Commun 1992;189:845-850.
46. Lu M and Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997;15:465-471.
47. Debnath AK, Radigan L, and Jiang S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J Med Chem 1999;42:3203-3209.
48. Jiang S, Lin K, Zhang L, and Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999;80:85-96.
49. Jiang S, Zhao Q, and Debnath AK: Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8:563-580.
50. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, and Broder S: 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
51. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-2488.
52. De Clercq E: Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000;57:833-839.
53. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, and Baroudy BM: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
54. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, and Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-588.
55. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, and Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
56. Moore JP, Trkola A, and Dragic T: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562.
57. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
58. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, and Mullins JI: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-10502.
59. Xiao L, Rudolph DL, Owen SM, Spira TJ, and Lal RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998;12:F137-F143.
60. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, and Moore JP: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
61. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, and O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
62. Barbouche R, Papandreou MJ, Miquelis R, Guieu R, and Fenouillet E: Relationships between the anti-HIV V(3)-derived peptide SPC(3) and lymphocyte membrane properties involved in virus entry: SPC(3) interferes with CXCR(4). FEMS Microbiol Lett 2000;183:235-240.
63. Fox S, Wang H, Sopchak L, and Khoury R: High throughput screening: Early successes indicate a promising future. J Biomol Screen 2001;6:137-140.
64. Sabbatini GP, Shirley WA, and Coffen DL: The integration of high throughput technologies for drug discovery. J Biomol Screen 2001;6:213-218.
65. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829-833.
66. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-835.
67. Moore K and Rees S: Cell-based versus isolated target screening: How lucky do you feel? J Biomol Screen 2001;6:69-74.